Physician profile
John Haynes
NPI 1578558722
$8,633.03
in general payments reported to CMS, 2019-2025
29 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $172 · 2021: $605 · 2022: $473 · 2023: $4,466 · 2024: $432 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,100 · Food and Beverage: $1,832 · Travel and Lodging: $1,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,099.99 |
| Food and Beverage | $1,832.12 |
| Travel and Lodging | $1,548.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,178.22 | 2019-2024 | Davinci Xi, Da Vinci Surgical System |
| Coloplast Corp | $1,174.60 | 2025 | |
| Abbvie INC. | $327.31 | 2019-2025 | |
| Coopersurgical, INC. | $317.76 | 2019-2023 | Summit Doppler, Mara Console |
| Lupin INC. | $312.42 | 2019-2021 | |
| Daiichi Sankyo INC. | $287.12 | 2019-2024 | Injectafer |
| Gynesonics, INC. | $230.50 | 2021-2022 | |
| Pfizer INC. | $215.33 | 2019-2025 | |
| Evofem Biosciences, INC. | $153.57 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.04 | 2019-2024 | |
| Avion Pharmaceuticals | $142.77 | 2019-2022 | |
| Myriad Women'S Health, INC. | $137.32 | 2023 | Myrisk |
| Organon LLC | $133.06 | 2021-2025 | Nexplanon, Jada System |
| Kowa Pharmaceuticals America, INC. | $125.00 | 2025 | Zoryve |
| Novo Nordisk INC | $125.00 | 2025 | Wegovy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $115.73 | 2024 | Veozah |
| Hologic Sales and Service, LLC | $92.79 | 2021-2024 | Myosure Tissue Removal Device, Novasure |
| Smith+Nephew, INC. | $70.08 | 2022-2023 | Grafix Pl, Stravix Pl, Stravix |
| Conmed Corporation | $61.11 | 2023 | Airseal |
| Exeltis, USA INC. | $50.86 | 2022-2023 | Slynd |
| Lilly USA, LLC | $50.56 | 2025 | Zepbound, Mounjaro |
| Therapeuticsmd, INC. | $39.02 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $27.23 | 2021 | |
| Duchesnay USA Incorporated | $26.37 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.18 | 2022 | |
| Stryker Corporation | $18.20 | 2019 | |
| Scynexis, INC. | $17.73 | 2022 | |
| Merck Sharp & Dohme LLC | $16.76 | 2019 | |
| Axonics, INC. | $14.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Haynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.